Vivos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
About Vivos Therapeutics
Surgical & Medical Instruments & Apparatus, SIC 3841
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing non-surgical treatments for patients suffering from obstructive sleep apnea (OSA), snoring, and related dentofacial abnormalities. Its primary offering is The Vivos Method, a multi-disciplinary treatment protocol utilizing proprietary oral appliances alongside clinical guidance. The company also provides home sleep testing services—such as the SleepImage ring—myofunctional therapy, and medical billing intelligence services. Through its management organizations, the business supports affiliated sleep testing centers and treatment facilities. Vivos Therapeutics serves adult and pediatric patients diagnosed with sleep breathing disorders, offering its products and clinical support through dentists, medical sleep specialists, physicians, and affiliated clinical practices.
The company is headquartered in Littleton, Colorado, where it maintains principal executive offices. Its clinical and administrative presence includes operations in Nevada following its acquisition of The Sleep Center of Nevada, with additional affiliations across the United States.
Summary of the business section of Vivos Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vivos Therapeutics, Inc.
- Headquarters
- Littleton, CO
- Address
- 7921 Southpark Plaza,, Suite 210 80120
- Phone
- (866) 908-4867
- Employees
- 268, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Denver, Colorado
Stock & identifiers
- Ticker
- VVOS
- Exchange
- Nasdaq
- IPO date
- Dec 14, 2020
- Shares outstanding
- 20M, Aug 13, 2026
- Public float
- $22.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Nov 14, 2023; 1-for-25 reverse, Oct 27, 2023
- SEC CIK
- 1716166
- CUSIP
- 92859E207
- ISIN
- US92859E2072
- EIN
- 81-3224056
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ronald Kirk Huntsman | Chief Executive Officer, Director | 158,971 |
| Bradford K. Amman | Principal Accounting Officer | 250,080 |
| Gregg C. Johnson | Director | 3,997 |
| Leonard J. Sokolow | Director | – |
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 268 full-time employees.”
Corporate history
Events identified from SEC filings